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Sir,
We acknowledge Dr Alliot’s letter and would like to respond to
the many points raised. Firstly, we would like to reiterate our
comments in the discussion that this regimen represents a viable
option for patients with metastatic colorectal cancer who have
previously received fluorouracil and irinotecan (Chong et al, 2005).
The results of our study should not necessarily be extrapolated to
patients who have previously received oxaliplatin or targeted
agents.
For a single-arm study of third-line therapy for advanced
colorectal cancer, the utility of biochemical prognostic factors in
interpreting treatment efficacy is likely to be small. Therefore,
these data have not been included. Of the 36 patients enrolled, 31
had liver metastases, and in eight patients, the primary tumour was
in situ. Nevertheless, the treatment efficacy of a third-line regimen
is not likely to be influenced by whether patients initially presented
with synchronous or metachronous metastatic disease. With
regard to the first-line 5-fluorouracil (5FU) regimen, a majority
of patients received bolus 5FU/leucovorin (LV) according to the
Mayo schedule; two patients received LV5FU2. There is no
evidence that LV5FU2 vs bolus 5FU/LV influences the efficacy of
subsequent chemotherapy.
The limited efficacy of capecitabine monotherapy for patients
who are 5FU-refractory has been well demonstrated previously
(Hoff et al, 2004). However, there are preclinical data suggesting
that the addition of mitomycin C (MMC) to capecitabine may be
synergistic. In patients with untreated advanced colorectal cancer,
the addition of MMC to capecitabine has been shown to produce
higher response rate than expected with capecitabine alone, (Rao
et al, 2004). The 15.4% response rate for the combination of MMC
and capecitabine observed in our study of pretreated patients is
therefore consistent with these data.
There are substantial data on the incidence of haemolytic
uraemic syndrome (HUS) in patients treated with MMC. The
incidence for patients receiving less than 30mgm
2 is very low
(Ross et al, 1997, 2002; Tebbutt et al, 2002). However, we agree that
patients receiving MMC, regardless of cumulative dose, should be
closely monitored for the development of HUS.
Clearly, our data are not directly applicable to patients who have
received first- or second-line oxaliplatin, bevacizumab or cetuxi-
mab. However, for patients who have not had (and will not have)
access to these drugs, the combination of capecitabine and MMC is
a potentially active one for patients with advanced colorectal
cancer.
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